How to Respond to an FDA Warning Letter

Receiving an FDA warning letter is a serious event for any food, supplement, or cosmetic brand. Warning letters are public, may trigger retailer audits, and can precede further enforcement if FDA finds the response inadequate. While every letter is fact-specific, understanding the typical response framework helps leadership act quickly and methodically.

What is an FDA warning letter?

An FDA warning letter is a formal notification that the agency believes a company is violating the Federal Food, Drug, and Cosmetic Act or related regulations. For advertising and labeling matters, common issues include unapproved drug claims, misleading statements, inadequate substantiation references, and misbranded labeling. Warning letters do not constitute final legal determinations, but they carry significant practical consequences. FDA Warning Letters database publishes letters that can affect partner and consumer perception.

How quickly must a company respond?

FDA typically requests a written response within 15 business days, though the deadline stated in the letter controls. Missing the deadline without communication can signal poor compliance culture. If full remediation cannot be completed in that window, many companies submit an interim response explaining completed steps, pending actions, and realistic completion dates.

What should a warning letter response include?

Effective responses are organized, itemized, and evidence-based. For each numbered observation or quoted claim, the company should state whether it agrees or respectfully disagrees, describe corrective action taken, attach proof of changes, and identify systemic fixes such as updated review procedures or training.

• A cover letter signed by a responsible official with contact information.
• Point-by-point responses mirroring FDA's structure in the warning letter.
• Screenshots, revised labels, updated URLs, or redlined copy showing corrections.
• Root-cause analysis explaining how the violation occurred.
• Preventive measures: SOP updates, claim approval workflows, and monitoring plans.

Should a company remove claims before responding?

In many advertising-related cases, firms immediately stop disseminating problematic claims and remove or revise web content, marketplace listings, and paid ads. Document the date and scope of takedowns. FDA often expects prompt remediation even while a formal response is being drafted. Continuing to run disputed claims while negotiating a response can escalate enforcement.

Coordinate internal teams early

Warning letter response is cross-functional. Legal, regulatory, marketing, e-commerce, and agency partners may all need to act. Natascia Taken, Esq. typically recommends a single response owner, a document preservation hold, and a inventory of all live claims across channels so nothing is missed during remediation.

What if the company disagrees with FDA's position?

Disagreement is possible but should be handled carefully. Responses may present legal and factual arguments with supporting evidence while still describing voluntary corrective steps where appropriate. Tone matters: FDA responds better to precise, respectful analysis than blanket denial without documentation. Some firms request meetings with FDA to discuss scientific or interpretive disputes.

What happens after FDA receives the response?

FDA reviews the response and may close the matter, request additional information, or take further action if corrections are incomplete. Follow-up inspections, continued monitoring of public materials, and secondary warning letters are possible when FDA believes violations persist. Companies should continue compliance audits after submitting the response — not treat submission as the finish line.

What documentation should be preserved during a warning letter response?

Preserve emails, Slack messages, agency drafts, analytics exports, and prior versions of web pages that FDA quoted. Litigation and follow-up enforcement sometimes develop months after the initial letter. A litigation hold prevents spoliation issues and helps reconstruct decision timelines if FDA questions whether corrections were prompt or complete.

Can a warning letter affect retailers and payment processors?

Yes. Major retailers, marketplaces, and payment processors monitor FDA enforcement databases. A public warning letter may trigger account reviews, product delistings, or requests for corrective action plans even before FDA closes the matter. Proactive communication with key commercial partners — with counsel involved — can sometimes reduce abrupt account suspensions while remediation is underway.

Should a company post its warning letter response publicly?

Generally, warning letter responses are submitted to FDA directly and are not required to be posted publicly unless FDA publishes them or the company chooses to share them. Some firms issue press statements summarizing corrective steps, but public statements should align with the official response and avoid creating new unsubstantiated claims while remediation is ongoing.

Timeline discipline matters. Create an internal tracker assigning owners and due dates for each cited violation, and verify completion with screenshots or signed attestations from responsible department heads before the response goes out.

What if FDA cites claims on archived or old web pages?

FDA can cite historical web content preserved in its review. Use the Wayback Machine and internal archives to identify how long problematic claims were live. Your response should address takedown dates and explain whether old pages might still be accessible through cached search results or third-party reposts.

This guide describes general practices and is not legal advice. Warning letter strategy depends on violation type, product classification, prior FDA history, and enforcement context. Consult qualified counsel promptly after receiving any FDA enforcement communication.